ELISA for IgM/IgG/IgA antibodies of COVID-19
COVID-19 IgM
Monitoring of the immune response to COVID-19, in the early stage of the infection as an additional marker to PCR
COVID-19 IgG
Monitoring of the immune response to COVID-19. Recommended in particular for testing:
(a) in follow-up serological testing and when recovered from the infection, negative for COVID-19 PCR, to assure they developed IgG antibodies to the virus, confirming a full recovery from the infection, infected individuals
(b) at risk of covid-19 infection to verify whether or not they developed IgG antibodies to the virus; health-care workers
(c) individuals from normal population to study their acquired immune status against COVID-19 infection.
(d) for a preliminary screening of hyper-immune sera as a possible candidate for an immunotherapeutic approach to the treatment of the disease. Human antibodies donors
COVID-19 IgG Confirmation
Module-based Enzyme-Immuno-Assay for the Confirmation/typing of human samples screened as positive for IgG. The test is aimed to identify the specificity of antibodies to the major immunodominant COVID-19 antigens Nucleocapsid, Spike 1 and Spike 2.
COVID-19 IgA
The IgA assay is recommended, in addition to IgG and IgM, to:
(a) monitor the global immunological response of patients undergoing an acute infection and their follow up to full recovery.
(b) specifically, for testing patients with symptoms of the gastro enteric form of COVID-19 infection
ELISA for IgM/IgG/IgA antibodies of COVID-19 
